

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition of matter in the form of a sterile comprising a cyclosporin dissolved in dimethyl sulfoxide (DMSO), wherein the concentration of cyclosporin is from 0.1% to ~~25%~~^{20%} by weight of the total composition, and wherein DMSO is present at least ~~75%~~^{80%} by weight in the composition.

2. (Previously Presented) A composition as in claim 1 wherein the cyclosporin is cyclosporin A.

3. (Previously presented) A method for administering cyclosporin into cerebrospinal fluid or cerebrospinal fluid spaces of a patient, which comprises:

providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and
administering said cyclosporin and DMSO sterile injectable solution by injection into the cerebrospinal fluid or cerebrospinal fluid spaces of said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

4. (Previously presented) A method for administering a sterile injectable solution of cyclosporin to a patient, which compromises:

providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and
administering said sterile injectable solution of cyclosporin and DMSO to said patient by intravestibular injection, into or adjacent to the brain, or spinal cord of said patient, wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

5. (Previously presented) A method for administering cyclosporin by injection including via intravenous, intra-arterial or intraparenchymal injection, into a patient, which compromises:

providing a sterile injectable solution of cyclosporin dissolved in DMSO according to claim 1 in a pharmaceutically acceptable carrier, and
administering said sterile injectable solution of cyclosporin and DMSO by injection into intravenous, intra-arterial or intraparenchymal spaces of said patient.

6. (Previously presented) A method for administering cyclosporin inhalationally or nasally to a patient, which compromises:
providing the cyclosporin dissolved in DMSO according to claim 1 in a pharmaceutically acceptable carrier, and
administering said cyclosporin and DMSO solution inhalationally or nasally to said patient.

7. (Previously Presented) The method of claim 3 wherein the cyclosporin is cyclosporin A or a salt thereof.

8. (Previously presented) An article of manufacture, comprising:
packaging material, and
a sterile injectable pharmaceutical agent that is therapeutically effective for reducing or treating neuronal damage and for causing immunosuppression when administered by injection in a therapeutically effective quantity,
wherein the packaging material comprises a label which indicates that the sterile injectable solution of pharmaceutical agent can be used for reducing or treating neuronal damage and for causing immunosuppression, and
wherein said sterile injectable pharmaceutical agent comprises:
a sterile injectable solution of one or more cyclosporins in DMSO according to claim 1.

9. (Previously Presented) The article of manufacture according to claim 8, wherein the cyclosporin is cyclosporin A or a salt thereof.

10. (Previously Presented) The method according to claim 3 wherein the administration of a sterile injectable solution of cyclosporin into cerebrospinal fluid spaces is intraventricular or intrathecal.

11. (Previously presented) A method for treating Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV neuropathy, Guillain-Barré syndrome, neural transplantation, neural xenotransplantation, stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity of vestibular structures, or retinal detachment, which comprises:

administering a sterile injectable solution of cyclosporin dissolved in DMSO according to claim 1 in a pharmaceutically acceptable carrier to said patient.

12. (Previously presented) A method for inducing systemic immunosuppression in a patient of transplantation or autoimmune disease, which comprises:
administering a sterile injectable solution of cyclosporin and DMSO according to claim 1 to said patient.

13. (Previously presented) The pharmaceutical composition according to claim 1, wherein said composition is formulated in a unit dosage amount of at least 5 mg/day.

14. (Previously presented) The pharmaceutical composition according to claim 1, wherein said composition is formulated in a unit dosage amount of at least 100 mg/day to at least 1000 mg/day.

15-20. (Cancelled)

21. (Currently amended) The method according to claim 3, wherein the sterile injectable solution of cyclosporin dissolved in DMSO comprises a cyclosporin dissolved in dimethyl sulfoxide (DMSO), wherein the concentration of cyclosporin is from 0.1% to 25%20% by

weight of the total composition, and wherein DMSO is present at least ~~75%~~^{80%} by weight in the composition.

22. (Currently amended) The pharmaceutical composition according to claim 1, wherein said composition is formulated in a unit dosage amount of at least 0.001 mg/kg body weight/day to at least 1000 mg/day.

23. (Previously presented) The pharmaceutical composition of claim 1, further comprising an additional pharmaceutically acceptable additive and/or an additional active ingredient.

24. (new) The method of claim 3, wherein a dose of from 50 to 150 mg/day of cyclosporin is administered.

25. (new) The method of claim 4, wherein a dose of from 50 to 150 mg/day of cyclosporin is administered.

26. (new) The composition of claim 22, formulated to provide a unit dosage of from 50 to 150 mg/day.